Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
5.36
-0.18 (-3.25%)
Sep 29, 2025, 3:19 PM EDT - Market open
Candel Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
38
Market Cap
294.24M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 125.00K | - | - |
| Dec 31, 2021 | 125.00K | - | - |
| Dec 31, 2020 | 125.00K | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
CADL News
- 7 hours ago - Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025 - GlobeNewsWire
- 12 days ago - Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025 - GlobeNewsWire
- 22 days ago - Candel Therapeutics: Potentially The Next Exciting Oncology Story - Seeking Alpha
- 24 days ago - Candel Therapeutics: Oncolytic Immunotherapy Showing Broad Efficacy In Tough Tumors - Seeking Alpha
- 27 days ago - Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D. - GlobeNewsWire
- 4 weeks ago - Candel Therapeutics to Participate in Upcoming Investor Conferences in September - GlobeNewsWire
- 6 weeks ago - Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 2 months ago - Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference - GlobeNewsWire